PLCG2 and autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation: PLCG2 mutations in position 707 are particularly intriguing, because they give rise to clinically disparate conditions: APLAID, when germline, and ibrutinib-resistant CLL, when somatic.